



November 10, 2023

**BSE Limited,**  
Floor 25, P. J. Towers  
Dalal Street, Fort  
**Mumbai - 400 001**

**National Stock Exchange of India Limited,**  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (E),  
**Mumbai - 400051**

**Scrip Code: 530019**

**Symbol: JUBLPHARMA**

Dear Sirs,

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**

This is to inform you that Jubilant Draximage Inc., USA (the 'Company'), a Wholly Owned Subsidiary of Jubilant Pharmova Limited, today announced that it has received an approval from the US FDA with regards to the Company's Abbreviated New Drug Application (ANDA) for preparation of Technetium Sulfur Colloid Injection which is effective from November 09, 2023. In this regard, please find enclosed herewith Press Release pursuant to Regulation 30 of Listing Regulations.

The above mentioned document will be simultaneously posted on the Company's website at [www.jubilantpharmova.com](http://www.jubilantpharmova.com).

We request you to take the same on record.

Thanking you,

Yours faithfully,

**For Jubilant Pharmova Limited**

Naresh Kapoor  
Company Secretary

Encl: as above

A Jubilant Bhartiya Company  
OUR VALUES



**Jubilant Pharmova Limited**  
1-A, Sector 16-A,  
Noida-201 301, UP India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
[www.jubilantpharmova.com](http://www.jubilantpharmova.com)

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223  
UP India  
CIN : L24116UP1978PLC004624



**Jubilant Pharmova Limited**  
1A, Sector 16A, Noida – 201301, India  
Tel.: +91 120 4361000  
[www.jubilantpharmova.com](http://www.jubilantpharmova.com)

**PRESS RELEASE**

**Noida, Friday, Nov 10, 2023**

## **Jubilant’s Radiopharma business receives ANDA approval for Technetium Sulfur Colloid Injection**

Jubilant Pharmova Limited’s wholly owned subsidiary Jubilant Draximage Inc (‘Company’) today announced that it has received approval from the US FDA with regards to the Company’s abbreviated new drug application (ANDA) submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C) for kit for the preparation of Technetium (Tc 99m) Sulfur Colloid Injection. For this approval, Jubilant is eligible for 180 days of exclusivity through the ‘Competitive Generic Therapy’ designation from the US FDA.

Technetium Sulfur Colloid Injection is used in the localization of metastatic lymph nodes in patients with breast cancer and melanoma, imaging of areas of the liver, spleen and bone marrow, and studies of esophageal transit, gastroesophageal reflux, and detection of pulmonary aspiration of gastric contents.

This approval is effective from Nov 9, 2023.

**Speaking on the announcement, Pramod Yadav, CEO, Jubilant Radiopharma business said,** “At Jubilant, we are glad to announce approval for Sulfur Colloid, which will improve availability of this critical radiopharmaceutical to patients and healthcare professionals. Technetium Sulfur Collid is our second product to be launched in FY24 after the approval and launch of Technetium Mertiatide Injection in Q1’FY24 and highlights our strong focus on the nuclear medicine business and commitment towards improving patient lives.”

### **About Jubilant Radiopharma**

Jubilant Radiopharma, a division of Jubilant Pharma Ltd., is an industry-leading radiopharmaceutical business that comprises development, manufacturing and commercialisation of products through Radiopharmaceuticals business and distribution through the Radiopharmacies business. Jubilant Radiopharma’s manufactured products are used in the diagnosis, treatment and monitoring of various diseases with specialisation in lung, thyroid, bone and cardiac imaging products as well as in thyroid disease therapy. The division’s Radiopharmacies business is the second largest radio pharmacy network in the US with 46 pharmacies distributing nuclear medicine products to the largest national Group Purchasing Organisations (GPOs), regional health systems, stand-alone imaging centres, cardiologists and hospitals. This business has over 30 years of experience in serving the US nuclear medicine community and its current geographical reach enables it to serve over four million patients yearly. The Radiopharmacies business complements the Company’s niche Radiopharmaceuticals business and provides it with direct access to hospital networks. Jubilant Radiopharma is focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of “Improving Lives through Nuclear Medicine” on a global scale.

### **About Jubilant Pharma Limited**

Jubilant Pharma Limited (JPL), a Company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of 46 radio-pharmacies in the US, Allergy

---



Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Solid Dosage Formulations through five manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. The Company has a team of around 3,200 multicultural people across the globe and is committed to delivering value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally. For more info please visit [www.jubilantpharma.com](http://www.jubilantpharma.com)

## **About Jubilant Pharmova Limited**

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is engaged in Radiopharma, Allergy Immunotherapy, CDMO of Sterile Injectable, Generics, Contract Research Development and Manufacturing (CRDMO) and Proprietary Novel Drugs businesses. With a network of 46 radio-pharmacies in the US, Jubilant's Radiopharma business is engaged in manufacturing and supply of Radiopharmaceutical products and services. Its other businesses such as Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Generics (Solid Dosage Formulations) caters to major regulated markets (USA, EU and other geographies) through five manufacturing facilities. The CRDMO segment (through Jubilant Biosys) provides collaborative research and partnership for Drug Discovery through two world class research centers in India. The company is also involved in the manufacturing of Active Pharmaceutical Products (API) through a US FDA approved facility in Nanjangud, Karnataka. Jubilant Therapeutics (JTI) invested for in-house Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Pharmova Limited has a team of over 5,500 multicultural people across the globe. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals companies globally. For more information, please visit: [www.jubilantpharmova.com](http://www.jubilantpharmova.com)

## **For more information, please contact:**

### **For Investors**

**Vineet V Mayer / Pankaj Dhawan**

Ph: +91 120 436 1103 / 1105

E-mail: [vineet.mayer@jubl.com](mailto:vineet.mayer@jubl.com) / [Pankaj.dhawan@jubl.com](mailto:Pankaj.dhawan@jubl.com)

## **Disclaimer**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

---